HEALTH INNOVATION NEXT GENERATION PAYMENT&PRICING MODELS: HI- PRIX PROJECT

健康创新下一代支付

• 批准号: 10062152
• 金额: $ 41.9万
• 依托单位: LONDON SCHOOL OF ECONOMICS & POL SCI
• 依托单位国家: 英国
• 项目类别: EU-Funded
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10062152
• 关键词: HEALTH; INNOVATION; NEXT; GENERATION; PAYMENT&PRICING

The variety of innovative technologies with the potential to revolutionize the delivery of health care means that the policy toolbox will need several pricing and payment models, adapted in their design and implementation according to the specific situation. Although there are examples of novel pricing and payment models, the lack of appropriate data infrastructure, legal barriers and unwillingness to adapt current systems often prevent their use. Therefore, the overall objectives of the Health Innovation Next Generation Pricing Models (HI – PRIX) project are: i) to map and formulate new pricing and payment schemes that can be used across technology classes, therapeutic areas, setting and healthcare systems/geographies together with a related set of principles that may guide successful adjustment and flexible implementation to the context of use; ii) to investigate the impact on competitiveness, innovation, equity and affordability of a pipeline of contracting modalities for health innovations; iii) to address the challenges and concerns of payers, manufacturers, healthcare professionals, and patients about different models of pricing by sustaining an effective dialogue across stakeholders’ groups about the trade-offs between affordability, innovation and patient access. Coordinated by Bocconi University, the HI-PRIX Consortium involves 18 partners from 10 European countries, including academic institutions, public authorities, healthcare providers, and independent research organizations. Through theoretical models, quantitative simulation, qualitative research work and case-studies, this three-year project structured around 10 WPs, will generate new evidence on the role of public sector in R&D and indirect medical and environmental costs in pricing and reimbursement determinations, on the pricing dynamics over pharmaceutical products’ lifecycle, on the impact of policies and incentives on the competitiveness, innovativeness and equity in the healthcare system.

具有彻底改变医疗保健提供的各种创新技术，这意味着策略工具箱将需要几种定价和支付模型，并根据特定情况在其设计和实施中进行改编。尽管有一些新颖的定价和支付模型的例子，但缺乏适当的数据基础架构，法律障碍和不愿适应当前系统的情况通常会阻止其使用。因此，健康创新下一代定价模型（HI – PRIX）项目的总体对象是：i）绘制和制定可在技术类别，治疗领域，设置和医疗保健系统/地理位置上使用的新定价和支付方案，以及可以指导使用成功的原理和灵活实施的相关原理； ii）调查对健康创新方式承包方式的竞争力，创新，公平和负担能力的影响； iii）解决付款人，制造商，医疗保健专业人员和患者的挑战和关注点，通过在利益相关者团体之间维持有关可用性，创新和患者访问之间的权衡的有效对话，以进行不同的定价模式。 HI-Prix联盟由Bocconi大学协调，涉及来自10个欧洲国家的18个合作伙伴，包括学术机构，公共当局，医疗保健提供者和独立的研究组织。通过理论模型，定量模拟，定性研究工作和案例实习，这个三年的项目构成了10个WP，将为公共部门在R＆D中的作用以及间接医疗和环境成本在定价和报销确定中的新证据，对制药产品的竞争力和侵略性的影响，并构成竞争力的影响力，并构成了竞争力的影响。医疗保健系统。